Katsufumi Mizushige
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katsufumi Mizushige has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Hirohide Matsuo
The Second Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan
10 shared publicationsKoji Ohmori
Second Department of Internal Medicine, Kagawa Medical University
6 shared publicationsKenichi Hirao
The Second Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan
4 shared publicationsMasakazu Kohno
Second Department of Internal Medicine, Kagawa Medical University, 1750-1 Miki, Kita, Kagawa 761-0793, Japan
4 shared publicationsShiro Nozaki
The Second Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan
4 shared publicationsTakahisa Noma
Second Department of Internal Medicine, Kagawa Medical University, Kita, Kagawa, Japan
4 shared publications
Latest Publications
- 1 April 2004
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 32 (2) , 170-175
Antioxidant Effect of a New Calcium Antagonist, Azelnidipine, in Cultured Human Arterial Endothelial Cells
Azelnidipine is a novel dihydropyridine-type calcium antagonist with long-acting anti-hypertensive action and a low reported incidence of tachycardia. We aimed to evaluate its antioxidant activity in cultured human arterial endothelial cells under oxidative stress. Endothelial cells were exposed to 1 mM H2O2 and treated with 100 μM α-tocopherol, 1 nM, 10 nM or 100 nM azelnidipine, 100 nM nifedipine or 100 nM amlodipine. After 3 h, the cell number and level of lipid peroxidation were evaluated by measuring the total protein and 8-iso-PGF2α concentrations, respectively. The total protein concentration was similar with each treatment. Inhibition of 8-iso-PGF2α was greatest with 10 nM azelnidipine (compared with the other drugs); the difference between 10 nM and 100 nM azelnidipine was not significant. We conclude that azelnidipine has a potent antioxidative effect that could be of significant clinical benefit when combined with its long-lasting anti-hypertensive action and low incidence of tachycardia.
- 1 April 2004
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 32 (2) , 170-175
Antioxidant Effect of a New Calcium Antagonist, Azelnidipine, in Cultured Human Arterial Endothelial Cells
Azelnidipine is a novel dihydropyridine-type calcium antagonist with long-acting anti-hypertensive action and a low reported incidence of tachycardia. We aimed to evaluate its antioxidant activity in cultured human arterial endothelial cells under oxidative stress. Endothelial cells were exposed to 1 mM H2O2 and treated with 100 μM α-tocopherol, 1 nM, 10 nM or 100 nM azelnidipine, 100 nM nifedipine or 100 nM amlodipine. After 3 h, the cell number and level of lipid peroxidation were evaluated by measuring the total protein and 8-iso-PGF2α concentrations, respectively. The total protein concentration was similar with each treatment. Inhibition of 8-iso-PGF2α was greatest with 10 nM azelnidipine (compared with the other drugs); the difference between 10 nM and 100 nM azelnidipine was not significant. We conclude that azelnidipine has a potent antioxidative effect that could be of significant clinical benefit when combined with its long-lasting anti-hypertensive action and low incidence of tachycardia.
- 25 February 2004
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 106 (4) , 284-288
The cerebrovascular dilatation effects of olprinone, a phosphodiesterase III inhibitor, in comparison with acetazolamide—a pliot study
- 25 February 2004
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 106 (4) , 284-288
The cerebrovascular dilatation effects of olprinone, a phosphodiesterase III inhibitor, in comparison with acetazolamide—a pliot study
- Open Access
- 1 December 2002
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 20 (4) , 329-340
Pioglitazone: Cardiovascular Effects in Prediabetic Patients
Pioglitazone is the second thiazolidine derivative used clinically in the type 2 diabetes mellitus (DM). In the prediabetic stage, hyperinsulinemia or insulin resistance has been suggested to be closely associated with the oxidative stress. The first thiazolidine derivative used to treat DM, troglitazone, is chemically related to α‐tocopherol, a known anti‐oxidant. Troglitazone prevents tissue damage, but has been reported to produce hepatotoxicity. Pioglitazone strongly increases insulin sensitivity, improves glucose and lipid metabolism and showed no evidence of hepatotoxicity. The mechanism of the antidiabetic action of pioglitazone involves activation of insulin receptors and /or high affinity for peroxisome proliferator‐activated receptor γ (PPARγ). Hydroxylation of the phenyl and pyridine rings in the chemical structure of pioglitazone may facilitate the scavenging of hydro‐xyl radicals. The direct antioxidant effect of pioglitazone may contribute to its effect on insulin resistance. The hypoglycemic and hypolipidemic effects of pioglitazone are likely to reduce the expression of TNFα. The reduction in the oxidative stress may lead to the suppression of TGFβ and of collagen accumulation. A decrease in collagen content is likely to improve left ventricular diastolic function and distensibility of the aortic wall. Reduction in the oxidative stress may prevent the proliferation of vascular smooth muscle cells and contribute to the decrease in the aortic wall stiffness.
- 1 December 2002
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 20 (4) , 329-340
Open AccessPioglitazone: Cardiovascular Effects in Prediabetic Patients
Pioglitazone is the second thiazolidine derivative used clinically in the type 2 diabetes mellitus (DM). In the prediabetic stage, hyperinsulinemia or insulin resistance has been suggested to be closely associated with the oxidative stress. The first thiazolidine derivative used to treat DM, troglitazone, is chemically related to α‐tocopherol, a known anti‐oxidant. Troglitazone prevents tissue damage, but has been reported to produce hepatotoxicity. Pioglitazone strongly increases insulin sensitivity, improves glucose and lipid metabolism and showed no evidence of hepatotoxicity. The mechanism of the antidiabetic action of pioglitazone involves activation of insulin receptors and /or high affinity for peroxisome proliferator‐activated receptor γ (PPARγ). Hydroxylation of the phenyl and pyridine rings in the chemical structure of pioglitazone may facilitate the scavenging of hydro‐xyl radicals. The direct antioxidant effect of pioglitazone may contribute to its effect on insulin resistance. The hypoglycemic and hypolipidemic effects of pioglitazone are likely to reduce the expression of TNFα. The reduction in the oxidative stress may lead to the suppression of TGFβ and of collagen accumulation. A decrease in collagen content is likely to improve left ventricular diastolic function and distensibility of the aortic wall. Reduction in the oxidative stress may prevent the proliferation of vascular smooth muscle cells and contribute to the decrease in the aortic wall stiffness.
- 1 September 2002
- Published by Wolters Kluwer Health in Hypertension
- Vol. 40 (3) , 251-255
Perindopril Effect on Uncoupling Protein and Energy Metabolism in Failing Rat Hearts
Uncoupling proteins, inner mitochondrial membrane proton transporters, are important for regulating myocardial energy efficiency. We investigated the effects of the ACE inhibitor perindopril on cardiac performance, myocardial energy efficiency, and uncoupling protein expression in an aortic regurgitation rat model. Twenty male Sprague-Dawley rats, in which aortic regurgitation was produced, were divided into untreated and perindopril-treated (5 mg · kg −1 · d −1 ) rats. The treatments were initiated 3 days after operation. Ten control rats were sham-operated. Measurements of blood pressure and echocardiography were repeated before and 100 days after operation (endpoint). Left ventricular uncoupling protein-2 expression, creatine phosphate, and adenosine triphosphate were measured at endpoint. In perindopril-treated rats, systolic and diastolic blood pressure decreased after treatment (92±4/65±2 mm Hg). At endpoint, left ventricular end-diastolic dimension in untreated (10.7±0.2 mm) and treated rats (9.2±0.2 mm) was increased, and fractional shortening was reduced in untreated rats (28±1%) but did not change in treated rats (36±2%). Uncoupling protein-2 mRNA expression increased in untreated rats (3.7-fold) and was suppressed by perindopril (1.5-fold). The creatine phosphate was reduced in untreated rats (10.6±0.7 μmol/g) but not in treated rats (15.9±2.0 μmol/g). In the chronic stage of aortic regurgitation, perindopril improved cardiac performance and myocardial energy efficiency, in which the suppression of uncoupling protein-2 may play an important role.
- 1 September 2002
- Published by Wolters Kluwer Health in Hypertension
- Vol. 40 (3) , 251-255
Perindopril Effect on Uncoupling Protein and Energy Metabolism in Failing Rat Hearts
Uncoupling proteins, inner mitochondrial membrane proton transporters, are important for regulating myocardial energy efficiency. We investigated the effects of the ACE inhibitor perindopril on cardiac performance, myocardial energy efficiency, and uncoupling protein expression in an aortic regurgitation rat model. Twenty male Sprague-Dawley rats, in which aortic regurgitation was produced, were divided into untreated and perindopril-treated (5 mg · kg −1 · d −1 ) rats. The treatments were initiated 3 days after operation. Ten control rats were sham-operated. Measurements of blood pressure and echocardiography were repeated before and 100 days after operation (endpoint). Left ventricular uncoupling protein-2 expression, creatine phosphate, and adenosine triphosphate were measured at endpoint. In perindopril-treated rats, systolic and diastolic blood pressure decreased after treatment (92±4/65±2 mm Hg). At endpoint, left ventricular end-diastolic dimension in untreated (10.7±0.2 mm) and treated rats (9.2±0.2 mm) was increased, and fractional shortening was reduced in untreated rats (28±1%) but did not change in treated rats (36±2%). Uncoupling protein-2 mRNA expression increased in untreated rats (3.7-fold) and was suppressed by perindopril (1.5-fold). The creatine phosphate was reduced in untreated rats (10.6±0.7 μmol/g) but not in treated rats (15.9±2.0 μmol/g). In the chronic stage of aortic regurgitation, perindopril improved cardiac performance and myocardial energy efficiency, in which the suppression of uncoupling protein-2 may play an important role.
- Open Access
- 1 September 2002
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 20 (3) , 163-174
Olprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects
Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive inotropic and vasodilator actions and improves myocardial mechanical efficiency. Second, olprinone augments cerebral blood flow by a direct vasodilatory effect on cerebral arteries. The cerebrovascular reactivity to olprinone is marked in patients with impaired cerebral circulation. Third, olprinone selectively improves carotid artery distensibility, which may be attributable to differences in the arterial structural components or the reactivity of smooth muscle cells to olprinone. Fourth, olprinone improves inadequate redistribution of brain perfusion and may prevent cerebral metabolic abnormalities in heart failure.
- 1 September 2002
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 20 (3) , 163-174
Open AccessOlprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects
Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive inotropic and vasodilator actions and improves myocardial mechanical efficiency. Second, olprinone augments cerebral blood flow by a direct vasodilatory effect on cerebral arteries. The cerebrovascular reactivity to olprinone is marked in patients with impaired cerebral circulation. Third, olprinone selectively improves carotid artery distensibility, which may be attributable to differences in the arterial structural components or the reactivity of smooth muscle cells to olprinone. Fourth, olprinone improves inadequate redistribution of brain perfusion and may prevent cerebral metabolic abnormalities in heart failure.
- 1 August 2001
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 27 (8) , 1079-1086
Ultrasonic tissue characterization can predict β-blocker efficacy in dilated cardiomyopathy
- 1 August 2001
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 27 (8) , 1079-1086
Ultrasonic tissue characterization can predict β-blocker efficacy in dilated cardiomyopathy
- Open Access
- 1 January 2001
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 65 (11) , 991-993
Fulminant Myocarditis in Polymyositis.
Cardiac involvement in patients with polymyositis is usually asymptomatic and associated with a mild clinical course. A female patient with muscle weakness and cardiogenic shock, who was diagnosed with polymyositis and fulminant myocarditis, is described. A large amount of methylprednisolone, in addition to intra-aortic balloon pumping and percutaneous cardiopulmonary support, led to the recovery of her cardiac function. However, a massive cerebral embolism occurred and she died. Postmortem histopathological examination showed necroses of muscles and diffuse invasion of mononuclear cells in both the myocardium and the biceps muscle of her arm. Although the mechanism of cardiac dysfunction is not clear, immunosuppressive therapy was effective for fulminant myocarditis in the present case. (Jpn Circ J 2001; 65: 991 - 993)
- 1 January 2001
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 65 (11) , 991-993
Open AccessFulminant Myocarditis in Polymyositis.
Cardiac involvement in patients with polymyositis is usually asymptomatic and associated with a mild clinical course. A female patient with muscle weakness and cardiogenic shock, who was diagnosed with polymyositis and fulminant myocarditis, is described. A large amount of methylprednisolone, in addition to intra-aortic balloon pumping and percutaneous cardiopulmonary support, led to the recovery of her cardiac function. However, a massive cerebral embolism occurred and she died. Postmortem histopathological examination showed necroses of muscles and diffuse invasion of mononuclear cells in both the myocardium and the biceps muscle of her arm. Although the mechanism of cardiac dysfunction is not clear, immunosuppressive therapy was effective for fulminant myocarditis in the present case. (Jpn Circ J 2001; 65: 991 - 993)
- Open Access
- 1 March 2000
- Published by SAGE Publications in Angiology
- Vol. 51 (3) , 223-230
Sensitive Detection of Myocardial Contraction Abnormality in Chronic Hemodialysis Patients by Ultrasonic Tissue Characterization with Integrated Backscatter
Since acoustic properties of the myocardium are sensitive to the myocardial structure and the contractile conditions of myocyte, the authors evaluated cardiac dysfunction based on the integrated ultrasonic backscatter in 18 hemodialysis (HD) patients (duration: 102 ±84 months, mean age: 57.6 ±9.7 years) and 11 age-matched normals. The cyclic variation of integrated backscatter (CV-IB) at interventricular septum (IVS) and left ventricular posterior wall (PW) was measured and compared with percent fractional short ening (%FS) and percent wall thickening (%Th). The CV-IB of HD patients was smaller than that of control subjects (IVS: 6.2 ± 1.1 dB vs 8.2 ± 1.1 dB, p = 0. 0003 and PW: 8.4 ±2.2 vs 10.3 ±1.3, p = 0.025). No significant difference was observed in %FS and %Th between HD patients and control subjects. In HD, the ratio of velocities of early diastolic inflow (E) to late atrial inflow was decreased (0.7 ±0.2 vs 1.1 ±0.7, p = 0.049) and decel eration time of E was prolonged significantly (200 ±28 msec vs 159 ±30 msec, p = 0.0082). In the absence of overt cardiac systolic dysfunction, myocardial damage indicated as a decrease in CV-IB and diastolic dysfunction identified on transmitral velocity waveform were detected, which may reflect from the myocardial fibrosis. As a mechanism, pressure overload, hyperparathyroidism, and anemia were neglected, and the other humoral factors may contribute to the myocardial damage in chronic renal failure.
- 1 March 2000
- Published by SAGE Publications in Angiology
- Vol. 51 (3) , 223-230
Open AccessSensitive Detection of Myocardial Contraction Abnormality in Chronic Hemodialysis Patients by Ultrasonic Tissue Characterization with Integrated Backscatter
Since acoustic properties of the myocardium are sensitive to the myocardial structure and the contractile conditions of myocyte, the authors evaluated cardiac dysfunction based on the integrated ultrasonic backscatter in 18 hemodialysis (HD) patients (duration: 102 ±84 months, mean age: 57.6 ±9.7 years) and 11 age-matched normals. The cyclic variation of integrated backscatter (CV-IB) at interventricular septum (IVS) and left ventricular posterior wall (PW) was measured and compared with percent fractional short ening (%FS) and percent wall thickening (%Th). The CV-IB of HD patients was smaller than that of control subjects (IVS: 6.2 ± 1.1 dB vs 8.2 ± 1.1 dB, p = 0. 0003 and PW: 8.4 ±2.2 vs 10.3 ±1.3, p = 0.025). No significant difference was observed in %FS and %Th between HD patients and control subjects. In HD, the ratio of velocities of early diastolic inflow (E) to late atrial inflow was decreased (0.7 ±0.2 vs 1.1 ±0.7, p = 0.049) and decel eration time of E was prolonged significantly (200 ±28 msec vs 159 ±30 msec, p = 0.0082). In the absence of overt cardiac systolic dysfunction, myocardial damage indicated as a decrease in CV-IB and diastolic dysfunction identified on transmitral velocity waveform were detected, which may reflect from the myocardial fibrosis. As a mechanism, pressure overload, hyperparathyroidism, and anemia were neglected, and the other humoral factors may contribute to the myocardial damage in chronic renal failure.